A 24-year-old male reported a 7-month hairline recovery using 0.5mg of dutasteride daily with no side effects. Another user suggested adding minoxidil to the treatment.
The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.
The user saw hair improvement with minoxidil, finasteride, and a red light cap, noting better results after adding finasteride and stressing routine consistency.
Inflammation plays a significant role in hair follicle miniaturization and androgenetic alopecia, with treatments like ketoconazole shampoo, minoxidil, and finasteride being used to address it. Users discuss the benefits of anti-inflammatory treatments and peptides like KPV, alongside traditional hair loss treatments, to improve scalp health and hair quality.
Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
A user discusses the legitimacy of Kintor's KX-826 for hair loss, available on Amazon through Koshine Biomedica. They decided to order it after finding a document linking Kintor and Koshine as collaborators.
The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.
A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.
A user shared their 5-month hair loss treatment progress, using 1mg finasteride, daily GHK-CU injections, keratin/biotin/MSM supplements, Pura D’Or shampoo and conditioner, Ayurvedic oil, ketoconazole thrice weekly, and weekly microneedling with topical GHK-CU. The post includes progress pictures.
A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.
The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
The user shared their 5-year hair journey, including a recent hair transplant of 2600 grafts, and their routine of using dutasteride, oral minoxidil, and ketrel. They are hopeful for high-density results and recommend starting treatment early.
Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.
A user shared their 7-month progress after a hair transplant, using dutasteride and minoxidil to maintain native hair. The transplant was done in Juarez, Mexico, and the user noted that medication is still necessary to prevent further hair loss.
A 21-year-old experiencing itchy and burning scalp with hair loss was diagnosed with MPB and scalp inflammation. They were prescribed Ketoconazole, Prednisone, Clindamycin, and Finasteride, and are considering trying antihistamines, dietary changes, and "nopoo" to alleviate symptoms.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
The conversation is a satirical discussion about a baby with hair loss using adult hair loss treatments like finasteride, minoxidil, and ketoconazole, as well as dermarolling, scalp massages, and plans for PRP sessions. Suggestions include various other treatments and humorous advice, reflecting the satire of the situation.
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are asked to share their experiences with Pyri/Koshine.
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.